CTSO - Company ID 0001175151
Cytosorbents Corp trades as CTSO. In its fiscal 2025 annual report the company posted revenue of $37.06M, up 4.1% from the prior year and net income of -$8.20M. This page tracks Cytosorbents Corp through 959 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Cytosorbents Corp's revenue grew from $9.53M to $37.06M, a compound annual growth rate of 16.3%. Net profit margin expanded from -123.5% to -22.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Annual report (amended) | 10-K/A | 2026-04-15 |
| Major company event | 8-K | 2026-04-02 |
| Annual report | 10-K | 2026-03-30 |
| Major company event | 8-K | 2026-03-25 |
| SCHEDULE 13G/A | - | 2026-02-13 |
| Insider trade | 4 | 2025-11-20 |
The largest companies sharing Cytosorbents Corp's SEC industry classification (surgical & medical instruments & apparatus).
Cytosorbents Corp reported revenue of $37.06M for fiscal year 2025, an increase of 4.1% year over year.
In its latest fiscal year Cytosorbents Corp reported a net loss of $8.20M.